Analysis of drug resistance and risk factors of community-acquired urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children
10.3760/cma.j.issn.2095-428X.2019.17.012
- VernacularTitle: 儿童社区获得性泌尿道感染产超广谱β-内酰胺酶大肠埃希菌的耐药性及危险因素分析
- Author:
Shaona SONG
1
;
Bili ZHANG
1
;
Wenhong WANG
1
;
Xuan ZHANG
1
;
Shuying FAN
1
;
Nan CHEN
2
Author Information
1. Department of Nephrology, Tianjin Children′s Hospital, Tianjin 300074, China
2. Department of Laboratory, Tianjin Children′s Hospital, Tianjin 300074, China
- Publication Type:Journal Article
- Keywords:
Urinary tract infection;
Escherichia coli;
Extended-spectrum β
-lactamase;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2019;34(17):1331-1334
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the drug resistance and risk factors of community-acquired urinary tract infection(UTI) caused by extended-spectrum β-lactamase(ESBLs)-producing Escherichia coli in children.
Methods:The clinical data of 125 children with community-acquired urinary tract infection caused by Escherichia coli were analyzed, who were hospitalized at Department of Pediatric Nephrology of Tianjin Children′s Hospital from June 2017 to June 2018.The ESBLs-producing group and the non ESBLs-producing group were named depending on the production of the ESBLs.WHONET 5.6 bacterial resistance monitoring software was used to calculate the drug resistance rate of bacteria.The drug resistance rate and clinical data were analyzed by adopting χ2 test and Fisher′s exact probability method, then, factors with statistical significance identified by single factor analysis were further analyzed by multivariate Logistic regression analysis.
Results:Among 125 strains of Escherichia coli, 68 strains(54.4%) were ESBLs-producing Escherichia coli and 57 strains(45.6%) were non ESBLs-producing.The drug resistance rates of ESBLs-producing Escherichia coli to penicillins, cephalosporins, quinolones and monocyclic beta-lactams were higher than those of non ESBLs-producing strains, and the drug resistance rates to Ampicillin, Piperacillin, Cefazolin, Cefuroxime, Ceftriaxone and Cefotaxime were nearly 100%.The resistance rates of ESBLs-producing strains to Imipenem, Meropenem, Amikacin, Furantoin, Cefotetan and Piperacillin/Tazobactam were lower (< 5%). Univariate analysis showed that there were significant differences in recurrent UTI (χ2=12.043, P<0.01) and use of third-generation cephalosporins in the past 3 months(χ2=28.545, P<0.01) between ESBLs-producing group and non ESBLs-producing group.Multivariate Logistic regression analysis showed that use of third-generation cephalosporins in the past 3 months was an independent risk factor of community-acquired UTI caused by ESBLs-producing Escherichia coli(OR=11.285, 95%CI: 3.140-39.134, Wald=13.972, P<0.01).
Conclusions:The isolation rate of ESBLs-producing Escherichia coli in children with community-acquired UTI is high, and the drug resistance rate is high, so children who used third-generation cephalosporins in the past 3 months were more likely to develop community-acquired UTI caused by ESBLs-producing Escherichia coli.
